SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1208)
Related Products (1208)
-
Recombinant Proteins (196)
-
Z-L(D-Val)G-CHN2
0 ImagesCat. No.: HY-108137APurity: 99.35%Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50=190 nM) via inhibition of SARS-COV-2 3CL pro protease.
-
K777 tosylate
0 ImagesCat. No.: HY-119293ACAS No.: 502960-91-0K777 tosylate is a potent, orally active and irreversible cysteine protease inhibitor. K777 tosylate is also a potent CYP3A4 inhibitor with an IC50 of 60 nM. K777 tosylate irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 tosylate is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 tosylate inhibits SARS-CoV and EBOV pseudovirus entry with IC50 values of 0.68 nM and 0.87 nM, respectively.
-
Ritonavir-13C,d3
0 ImagesCat. No.: HY-90001S1CAS No.: 2937755-89-8Synonyms: ABT 538-13C,d3; RTV-13C,d3
-
Z-Leu-Leu-Leu-fluoromethyl ketone
0 ImagesCat. No.: HY-P5975CAS No.: 371167-61-2Synonyms: Z-LLL-FMK
-
Fluphenazine dihydrochloride (Standard)
0 ImagesFluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
-
SARS-CoV-2-IN-20
0 ImagesCat. No.: HY-146381CAS No.: 1260244-33-4SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of SARS-CoV-2 with an EC50 of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases.
-
SARS-CoV-2-IN-12
0 ImagesCat. No.: HY-145435CAS No.: 2721455-52-1SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19.
-
SARS-CoV-2 Mpro-IN-9
0 ImagesSARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM).
-
SARS-CoV-2 3CLpro-IN-39
0 ImagesCat. No.: HY-184687SARS-CoV-2 3CLpro-IN-39 (compound 7c) is a broad-spectrum antiviral agent and 3CLpro inhibitor that inhibits SARS-CoV-2, HCoV-OC43, HCoV-HKU1 and HCoV-NL63 3CLpro with IC50 values of 20, 710, 22 and 470 nM, respectively. SARS-CoV-2 3CLpro-IN-39 functionally inhibits the 3CLpro enzymatic activity of different coronaviruses. SARS-CoV-2 3CLpro-IN-39 exhibits anti-SARS-CoV-2 and anti-HCoV-NL63 activities. SARS-CoV-2 3CLpro-IN-39 can be used in the research of coronavirus infections.
-
SARS-CoV-2-IN-27 disodium
0 ImagesCat. No.: HY-151271ASARS-CoV-2-IN-27 disodium is a two-armed diphosphate ester with C6 alkyl and molecular tweezers with extended length. SARS-CoV-2-IN-27 disodium exhibits antiviral activity with IC50s of 1.0 μM and 1.7 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-27 disodium induces liposomal membrane disruption with an EC50 value of 6.5 μM.
-
Artecanin
0 ImagesCat. No.: HY-127083CAS No.: 29431-84-3Artecanin is a SARS-CoV-2 main protease (Mpro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of Mpro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with Mpro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19.
-
NSC111552
0 ImagesCat. No.: HY-153719CAS No.: 40420-48-2NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM.
-
Antimicrobial agent-11
0 ImagesCat. No.: HY-151501Antimicrobial agent-11 is a SARS-CoV-2 inhibitor with antibacterial activity.
-
SARS 3CLpro-IN-1
0 ImagesCat. No.: HY-150691CAS No.: 2409178-86-3SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole.
-
SARS-CoV-2-IN-84
0 ImagesCat. No.: HY-162414CAS No.: 214221-82-6SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ).
-
Antioxidant agent-9
0 ImagesCat. No.: HY-P4307CAS No.: 71835-79-5Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as SARS-CoV-2 antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768).
-
SARS-CoV-2-IN-11
0 ImagesCat. No.: HY-145277CAS No.: 2722635-28-9SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
